Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial - Scorecard - MDSpire

Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial

  • By

  • Wei Xie

  • Lin-Jie Zhang

  • Chunxian Yue

  • Baojie Wang

  • Shougang Guo

  • Xuegan Lian

  • Chao Zhang

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of Safety and Effectiveness of B-cell Depleting Agents Combined with Daratumumab in Patients with Autoimmune Encephalitis: Protocol for a Multicenter Randomized Trial (RADIA)

At a Glance

CategoryDetail
Condition
Key MechanismsB-cell depleting agents (e.g., ofatumumab) followed by daratumumab targeting plasma cells, emphasizing their sequential use.
Target Population
Care Setting

Key Highlights

  • secondary_outcomes

Guideline-Based Recommendations

Diagnosis

    Management

    • A
    • d
    • d
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • e
    • x
    • a
    • m
    • p
    • l
    • e
    • s
    • o
    • f
    • B
    • -
    • c
    • e
    • l
    • l
    • d
    • e
    • p
    • l
    • e
    • t
    • i
    • n
    • g
    • t
    • h
    • e
    • r
    • a
    • p
    • y
    • a
    • n
    • d
    • c
    • y
    • c
    • l
    • o
    • p
    • h
    • o
    • s
    • p
    • h
    • a
    • m
    • i
    • d
    • e
    • u
    • s
    • a
    • g
    • e
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clarify the comparative effectiveness of ofatumumab followed by daratumumab against standard treatments.

        Clinical Best Practices

        • best_practices

        Related Resources & Content

        Original Source(s)

        Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial

        • by Wei Xie, Lin-Jie Zhang, Chunxian Yue, Baojie Wang, Shougang Guo, Xuegan Lian, Chao Zhang

        • May 29, 2026

        Related Content

        Digging deeper into NINJ1: its multifaceted role in central nervous system diseases

        Electroencephalographic abnormalities and clinical phenotypes in children with autism spectrum disorder: a single center cohort study

        Analysis of risk factors for hemorrhagic transformation after mechanical thrombectomy in acute anterior circulation large vessel occlusion stroke and construction of a nomogram prediction model